Journal
FRONTIERS IN IMMUNOLOGY
Volume 10, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2019.02388
Keywords
toll-like receptors; immuno-oncology; anti-cancer immunity; tumor rejection; immunotherapy
Categories
Funding
- Intramural Research Program of NIAID, NIH, National Institutes of Health [1R01AI123820-01]
- International Centre for Cancer Vaccine Science project of the International Research Agendas program of the Foundation for Polish Science - European Union under the European Regional Development Fund at the University of Gdansk [MAB/2017/03]
Ask authors/readers for more resources
In recent years, a lot of scientific interest has focused on cancer immunotherapy. Although chronic inflammation has been described as one of the hallmarks of cancer, acute inflammation can actually trigger the immune system to fight diseases, including cancer. Toll-like receptor (TLR) ligands have long been used as adjuvants for traditional vaccines and it seems they may also play a role enhancing efficiency of tumor immunotherapy. The aim of this perspective is to discuss the effects of TLR stimulation in cancer, expression of various TLRs in different types of tumors, and finally the role of TLRs in anti-cancer immunity and tumor rejection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
